Altamira Therapeutics Secures Patent for Allergy Relief Nasal Spray, Bentrio
Altamira Therapeutics Ltd. (OTCQB: CYTOF), a biopharmaceutical company specializing in the development of innovative treatments for various medical conditions, made a significant announcement on March 7, 2025. The U.S. Patent and Trademark Office (USPTO) issued a Notice of Allowance for patent application #17/466,142, which covers the composition of Bentrio, a nasal spray developed and commercialized by Altamira’s affiliate, Medica, for preventing or treating allergic rhinitis.
Key Composition and Intellectual Property Protection
The patent claims are directed towards the key ingredients and proprietary formulation of Bentrio. This intellectual property protection is expected to provide significant benefits for Altamira in the USA, the world’s largest market for over-the-counter (OTC) products for allergic rhinitis relief and treatment. The patent will have an initial priority date of September 8, 2020.
Impact on Altamira and the Allergy Relief Market
This patent issuance represents a major milestone for Altamira as it strengthens their position in the allergy relief market. With this patent, Altamira will have exclusive rights to manufacture, use, and sell the Bentrio formulation in the USA. The company’s share price responded positively to the news, with a significant increase in trading volume and stock price. This patent also validates the innovation and research efforts put into developing Bentrio.
Global Impact on Allergy Sufferers
The patent issuance could lead to improved options for allergy sufferers in the USA. Bentrio, a unique nasal spray, offers a convenient and effective solution for preventing or treating allergic rhinitis symptoms. With this patent protection, Altamira can invest more resources into research and development, potentially leading to new innovations and improvements for the allergy relief market. Additionally, this patent could pave the way for potential licensing or partnership opportunities, allowing more people to access Bentrio and its benefits.
Conclusion
Altamira Therapeutics’ patent issuance for Bentrio, a nasal spray for allergic rhinitis relief, is a significant achievement for the company. The patent protection in the USA strengthens Altamira’s position in the allergy relief market and validates their research efforts. This patent could lead to improved options for allergy sufferers in the USA and potential new innovations in the allergy relief market. As a result, investors, patients, and industry experts are closely monitoring Altamira’s progress and future developments.
- Altamira Therapeutics secures patent for Bentrio, a nasal spray for allergic rhinitis relief
- Patent covers key ingredients and composition of Bentrio’s proprietary formulation
- Expected to provide significant intellectual property protection in the USA
- Strengthens Altamira’s position in the allergy relief market
- Could lead to new innovations and improvements for the allergy relief market
